Crossmark

Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas

Crossref DOI link: https://doi.org/10.1007/s12020-018-1702-5

Published Online: 2018-09-20

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Hai Yan

Zhai, Weiwei

Tang, Hao

Hui, Guo Zhen

Wu, Zhe Bao
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81471392)

National Natural Science Foundation of China (81671371)
License Information

Text and Data Mining valid from 2018-09-20
More Information

Article History

Received: 26 April 2018

Accepted: 26 July 2018

First Online: 20 September 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.